ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)

Patrick C. Ma

doi:10.21037/pcm-2020-mnsclc-10

ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)

Patrick C. Ma

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Article number	6
Journal	Precision Cancer Medicine
Volume	4
Issue number	March
DOIs	https://doi.org/10.21037/pcm-2020-mnsclc-10
State	Published - Mar 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Anesthesiology and Pain Medicine
Oncology(nursing)
Oncology
Cancer Research
Surgery

Access to Document

10.21037/pcm-2020-mnsclc-10

Cite this

@article{e63476858b194723bafc7757b96c9a80,

title = "ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)",

author = "Ma, \{Patrick C.\}",

note = "Funding Information: uniform disclosure form (available at http://dx.doi. org/10.21037/pcm-2020-mnsclc-10). The series “Evidence and Controversies in the treatment of metastatic NSCLC” was commissioned by the editorial office without any funding or sponsorship. The author has the following potential conflicts of interest to declare. Dr. Ma reports grants and personal fees from Merck, grants and personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, grants and personal fees from Apollomics, grants from LOXO, grants from Medimmune, grants from",

year = "2021",

month = mar,

doi = "10.21037/pcm-2020-mnsclc-10",

language = "English (US)",

volume = "4",

journal = "Precision Cancer Medicine",

issn = "2617-2216",

publisher = "AME Publishing Company",

number = "March",

}

TY - JOUR

T1 - ADAURA

T2 - The role of adjuvant EGFR TKI and future consideration (Pro)

AU - Ma, Patrick C.

N1 - Funding Information: uniform disclosure form (available at http://dx.doi. org/10.21037/pcm-2020-mnsclc-10). The series “Evidence and Controversies in the treatment of metastatic NSCLC” was commissioned by the editorial office without any funding or sponsorship. The author has the following potential conflicts of interest to declare. Dr. Ma reports grants and personal fees from Merck, grants and personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, grants and personal fees from Apollomics, grants from LOXO, grants from Medimmune, grants from

PY - 2021/3

Y1 - 2021/3

UR - https://www.scopus.com/pages/publications/85110710974

UR - https://www.scopus.com/pages/publications/85110710974#tab=citedBy

U2 - 10.21037/pcm-2020-mnsclc-10

DO - 10.21037/pcm-2020-mnsclc-10

M3 - Review article

AN - SCOPUS:85110710974

SN - 2617-2216

VL - 4

JO - Precision Cancer Medicine

JF - Precision Cancer Medicine

IS - March

M1 - 6

ER -

ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this